Xue Ling Bo, Liu Yong Hong, Zhang Bo, Yang Yan Fang, Yang Dong, Zhang Li Wei, Jin Jian, Li Jie
Thyroid and Breast Surgery.
Anesthesiology Department, Cangzhou Central Hospital.
Medicine (Baltimore). 2019 Jan;98(1):e13842. doi: 10.1097/MD.0000000000013842.
We aimed to evaluate the correlation of neutrophil-to-lymphocyte ratio (NLR) with pathological response, disease-free survival (DFS), and overall survival (OS) in patients with breast cancer and under neoadjuvant chemotherapy (NAC).
We performed a systematical search using Cochrane Library, ScienceDirect, PubMed, Embase, and Web of Science up to May 2018. On the basis of the data directly obtained from the available studies, the odds ratios (ORs) and their 95% confidence intervals (95% CIs) were pooled on the basis of higher or lower NLR levels.
The meta-analysis showed that high NLR was significantly associated with poor NAC response (OR = 2.27, 95% CI: 1.46-3.53, P < .001) but not with the DFS (OR = 1.18, 95% CI: 0.78-1.78, P = .435) and OS (OR = 2.781, 95% CI: 0.54-14.32, P = .221).
Although high NLR was significantly associated with poor pathological response, we were unable to demonstrate the prognostic value of NLR for DFS and OS in patients with breast cancer who were undergoing NAC.
我们旨在评估中性粒细胞与淋巴细胞比值（NLR）与接受新辅助化疗（NAC）的乳腺癌患者的病理反应、无病生存期（DFS）和总生存期（OS）之间的相关性。
我们使用Cochrane图书馆、ScienceDirect、PubMed、Embase和Web of Science进行了系统检索，截至2018年5月。根据从现有研究中直接获得的数据，根据NLR水平的高低汇总比值比（OR）及其95%置信区间（95%CI）。
荟萃分析表明，高NLR与NAC反应不良显著相关（OR = 2.27，95%CI：1.46 - 3.53，P <.001），但与DFS（OR = 1.18，95%CI：0.78 - 1.78，P =.435）和OS（OR = 2.781，95%CI：0.54 - 14.32，P =.221）无关。
虽然高NLR与不良病理反应显著相关，但我们无法证明NLR对接受NAC的乳腺癌患者的DFS和OS的预后价值。
